Vertos Medical said today it won national coverage for its Mild procedure designed to treat lumbar spinal stenosis from the Centers for Medicare & Medicaid Services.
The Mild procedure won coverage through a recently approved study as part of CMS’ Coverage with Evidence Development Program, the Aliso Viejo, Calif.-cased company said.
Access to the procedure was granted via a CMS-approved claims-analysis study which will passively collect and analyze real-world data on the procedure.
“Patient and physician demand for the Mild procedure has grown a great deal, and I’m excited to hear that my patients and fellow practitioners will now have access to this effective, proven method for relieving pain and getting people back to doing the things that make life enjoyable. Neurogenic claudication related to lumbar spinal stenosis can be extremely life limiting; this first-line treatment stands to benefit the many patients currently being treated for LSS in the United States, who have no viable treatment options,” Dr. Nagy Mekhail of the Cleveland Clinic said in a prepared statement.
Vertos Medical’s Mild treatment is a minimally invasive procedure to treat lumbar spinal stenosis and reduce pain, and requires no stitches, general anesthesia, implants or overnight hospital stays, according to the company.
“This is great news for the thousands of people who suffer from the debilitating symptoms related to their lumbar spinal stenosis with neurogenic claudication, who have struggled to find a safe, effective, low-cost solution,” prez & CEO Eric Wichems said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.